Olaparib is a drug that kills cancer cells, and is already recommended by NICE as an option for patients with this type of ovarian cancer (BRCA-mutated, platinum-sensitive) who have had three or more courses of platinum‑based chemotherapy. The drug has now been trialled in tablet form for patients who have received at least two prior lines of platinum-based chemotherapy. This new tablet formulation of olaparib could ease the treatment burden for patients – reducing the number of pills taken from 16 capsules to four tablets per day.
Olaparib (Lynparza) tablets for recurrent platinum-sensitive BRCA-mutated ovarian cancer – maintenance therapy
Interventions: Olaparib (Lynparza; MK-7339; AZD2281; AZD-2281)
Indications: Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer
Therapeutic Areas: Female Reproductive Cancer